Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics

    Access Status
    Fulltext not available
    Authors
    Lonn, E.
    Bosch, J.
    Pogue, J.
    Avezum, A.
    Chazova, I.
    Dans, A.
    Diaz, R.
    Fodor, G.
    Held, C.
    Jansky, P.
    Keltai, M.
    Keltai, K.
    Kunti, K.
    Kim, J.
    Leiter, L.
    Lewis, B.
    Liu, L.
    Lopez-Jaramillo, P.
    Pais, P.
    Parkhomenko, A.
    Peters, R.
    Piegas, L.
    Reid, Christopher
    Sliwa, K.
    Toff, W.
    Varigos, J.
    Xavier, D.
    Yusoff, K.
    Zhu, J.
    Dagenais, G.
    Yusuf, S.
    HOPE-3 Investigators
    Date
    2015
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Lonn, E. and Bosch, J. and Pogue, J. and Avezum, A. and Chazova, I. and Dans, A. and Diaz, R. et al. 2015. Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. Canadian Journal of Cardiology. 32 (3): pp. 311-318.
    Source Title
    Can J Cardiol
    DOI
    10.1016/j.cjca.2015.07.001
    School
    Department of Health Policy and Management
    URI
    http://hdl.handle.net/20.500.11937/37425
    Collection
    • Curtin Research Publications
    Abstract

    BACKGROUND: Cholesterol and blood pressure (BP) can be effectively and safely lowered with statin drugs and BP-lowering drugs, reducing major cardiovascular (CV) events by 20%-30% within 5 years in high-risk individuals. However, there are limited data in lower-risk populations. The Heart Outcomes Prevention Evaluation-3 (HOPE-3) trial is evaluating whether cholesterol lowering with a statin drug, BP lowering with low doses of 2 antihypertensive agents, and their combination safely reduce major CV events in individuals at intermediate risk who have had no previous vascular events and have average cholesterol and BP levels. METHODS: A total of 12,705 women 65 years or older and men 55 years or older with at least 1 CV risk factor, no known CV disease, and without any clear indication or contraindication to the study drugs were randomized to rosuvastatin 10 mg/d or placebo and to candesartan/hydrochlorothiazide 16/12.5 mg/d or placebo (2 × 2 factorial design) and will be followed for a mean of 5.8 years. The coprimary study outcomes are the composite of CV death, nonfatal myocardial infarction (MI), and nonfatal stroke and the composite of CV death, nonfatal MI, nonfatal stroke, resuscitated cardiac arrest, heart failure, and arterial revascularization. RESULTS: Participants were recruited from 21 countries in North America, South America, Europe, Asia, and Australia. Mean age at randomization was 66 years and 46% were women. CONCLUSIONS: The HOPE-3 trial will provide new information on cholesterol and BP lowering in intermediate-risk populations with average cholesterol and BP levels and is expected to inform approaches to primary prevention worldwide (HOPE-3 ClinicalTrials.govNCT00468923).

    Related items

    Showing items related by title, author, creator and subject.

    • Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
      Yusuf, S.; Bosch, J.; Dagenais, G.; Zhu, J.; Xavier, D.; Liu, L.; Pais, P.; López-Jaramillo, P.; Leiter, L.; Dans, A.; Avezum, A.; Piegas, L.; Parkhomenko, A.; Keltai, K.; Keltai, M.; Sliwa, K.; Peters, R.; Held, C.; Chazova, I.; Yusoff, K.; Lewis, B.; Jansky, P.; Khunti, K.; Toff, W.; Reid, Christopher; Varigos, J.; Sanchez-Vallejo, G.; McKelvie, R.; Pogue, J.; Jung, H.; Gao, P.; Diaz, R.; Lonn, E.; HOPE-3 Investigators (2016)
      BACKGROUND: Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated ...
    • Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease
      Yusuf, S.; Lonn, E.; Pais, P.; Bosch, J.; López-Jaramillo, P.; Zhu, J.; Xavier, D.; Avezum, A.; Leiter, L.; Piegas, L.; Parkhomenko, A.; Keltai, M.; Keltai, K.; Sliwa, K.; Chazova, I.; Peters, R.; Held, C.; Yusoff, K.; Lewis, B.; Jansky, P.; Khunti, K.; Toff, W.; Reid, Christopher; Varigos, J.; Accini, J.; McKelvie, R.; Pogue, J.; Jung, H.; Liu, L.; Diaz, R.; Dans, A.; Dagenais, G.; HOPE-3 Investigators (2016)
      BACKGROUND: Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol increase the risk of cardiovascular disease. Lowering both should reduce the risk of cardiovascular events substantially. METHODS: ...
    • Effectiveness of blood pressure-lowering drug treatment by levels of absolute risk: Post hoc analysis of the Australian National Blood Pressure Study
      Ho, C.; Breslin, M.; Doust, J.; Reid, Christopher; Nelson, M. (2018)
      Objectives: In many current guidelines, blood pressure (BP)-lowering drug treatment for primary prevention of cardiovascular disease (CVD) is based on absolute risk. However, in clinical practice, therapeutic decisions ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.